Q32 Bio Inc. (QTTB) Stock Price & Analysis
Q32 Bio Inc. (QTTB) closed at USD 8.8 on Thursday, October 22, 2026, up 1.50% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 8.67; the Oct 22, 2026 session ranged USD 8.6–9.01 on volume of 363,636 shares. Market capitalization is $261.97M, with a 52-week range of USD 1.91–23.57 (NCM). Source: Nexqual, retrieved October 23, 2026 at 10:12 UTC.
Also available as compact Markdown for AI agents: nexqual.com/QTTB.md
Key facts (QTTB)
- Valuation: P/E 7.8x (avg 1.4x at the last 1 fiscal year-ends).
- Analysts: Buy (mean 1.86 on a 1–5 scale) (7 analysts), mean target USD 39.67 (range 29–59).
- Total return with dividends: 1Y +214.3% vs S&P 500 +14.9%; 5Y -91.8% vs S&P 500 +80.3%.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (QTTB)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $34.0M | $3.2M | $1.2M | $0K | $53.7M | — |
| Operating income | -$95.9M | -$133M | -$48.3M | -$66.1M | $16.9M | $21.5M |
| Net income | -$95.8M | -$5.0M | -$53.7M | -$47.7M | $29.8M | $33.8M |
| EPS (diluted) | -$31.14 | -$1.62 | -$153.96 | -$6.58 | $2.42 | — |
| Free cash flow | -$112M | -$115M | -$18.7M | -$67.8M | -$33.5M | — |
| Operating margin | -282.4% | -4154.6% | -4174.3% | — | 31.5% | — |
| Net margin | -281.9% | -156.0% | -4649.0% | — | 55.5% | — |
| Revenue growth | +1157.3% | -90.6% | -64.0% | -100.0% | — | — |
| Cash + short-term investments | $156M | $175M | $25.6M | $78.0M | — | — |
| Total debt | — | $30.0M | $38.6M | $0K | — | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (QTTB)
P/E 7.8x · P/B 2.5x · Earnings yield 12.90%
P/E at fiscal year-ends: Dec 2025 1.4x.
Analysts (QTTB)
Consensus Buy (mean 1.86 on a 1–5 scale), 7 analysts; mean target USD 39.67 (low 29, high 59).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-12 | Leerink Partners | Initiated | Outperform | $40 |
| 2026-09-28 | Jefferies | Initiated | Buy | $29 |
| 2026-08-24 | Morgan Stanley | Initiated | Overweight | $34 |
| 2026-07-28 | HC Wainwright & Co. | Target raised | Buy | $13 → $36 |
| 2026-07-13 | Oppenheimer | Target raised | Outperform | $20 → $40 |
| 2026-07-13 | Wells Fargo | Upgrade | Equal-Weight → Overweight | $66 |
Total return (dividends reinvested) (QTTB)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +214.3% | -91.8% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +215.5% | -39.4% |
| Volatility (annualized) | 141.8% | 134.7% |
| Max drawdown | -64.8% (Jul 2026→Oct 2026) | -98.8% (Nov 2021→Jun 2025) |
Companies that name QTTB in their SEC reports
| Relationship to QTTB | Company | Filing | Sentence |
|---|---|---|---|
| partner | Akebia Therapeutics, Inc. (AKBA) | 10-K Feb 26, 2026 | “In November 2025, we entered into an asset purchase agreement with Q32 Bio Inc. and Q32 Bio Operations Inc., together Q32, pursuant to which we purchased and assumed substantially all assets and liabilities of Q32 and its” |
QTTB analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.33 | $-0.38 | -14.0% | $0 | 7 |
| Next quarter (ends Dec 2026) | $-0.30 | $-0.37 | -18.8% | $333,330 | 7 |
| Current fiscal year (ends Dec 2026) | $-1.50 | $-1.74 | -13.7% | $333,330 | 7 |
| Next fiscal year (ends Dec 2027) | $-2.27 | $-1.97 | +15.0% | $833,330 | 7 |
Key Statistics (as of October 23, 2026 at 10:12 UTC)
| Price | USD 8.8 |
|---|---|
| Change | ▲ 1.50% (up) |
| Previous Close | USD 8.67 |
| Open | USD 8.67 |
| Day Range | USD 8.6 – 9.01 |
| 52-Week Range | USD 1.91 – 23.57 |
| Volume | 363,636 shares |
| Market Cap | $261.97M |
| Exchange | NCM |
Technical Analysis (QTTB)
Nexqual's technical model rates QTTB "SELL" based on 2 bullish and 4 bearish signals across 127 daily candles, as of October 23, 2026 at 10:12 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 45.66 (neutral) |
| vs SMA50 | Below (USD 11.26) |
| MACD | -0.72 (negative) |
Analyst Ratings (QTTB)
Wall Street analysts rate QTTB "Buy" based on 7 analysts, with a mean price target of USD 39.67 (range USD 29–59), per Nexqual as of October 23, 2026 at 10:12 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 39.67 |
| High Target | USD 59 |
| Low Target | USD 29 |
| Buy / Hold / Sell | 7 / 0 / 0 |
Earnings (QTTB)
| Revenue Estimate | $0 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.44 vs est -0.54 ▲ beat |
| 2026-03-31 | USD -0.54 vs est -0.68 ▲ beat |
| 2025-12-31 | USD 4.58 vs est -0.86 ▲ beat |
| 2025-09-30 | USD -0.6 vs est -1.19 ▲ beat |
Source: Nexqual, October 23, 2026 at 10:12 UTC.
Financials & Fundamentals (QTTB)
| Total Revenue | $53.74M |
|---|---|
| Gross Margin | +73.30% |
| Operating Margin | +39.94% |
| Profit Margin | +62.87% |
| ROE | +72.14% |
| Debt / Equity | 0.05 |
| Current Ratio | 20.3 |
| Total Cash | $106.27M |
| Total Debt | $5.30M |
| Free Cash Flow (fiscal year ended Dec 2025, SEC 10-K) | -$33.54M (-62.4% of revenue) |
Source: Nexqual, October 23, 2026 at 10:12 UTC.
Financial Health Score (QTTB)
Nexqual rates Q32 Bio Inc.'s overall financial health "Solid" across five dimensions, as of October 23, 2026 at 10:12 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Strong — Gross margin 73%, operating 40% (last 12 months) |
| Balance Sheet | Strong — $106M cash vs $5M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$34M (FY ended Dec 2025, 10-K), burning cash |
| Efficiency | Strong — ROE 72%, ROA 14.7% |
Ownership (QTTB)
| Insider Ownership | +2.08% |
|---|---|
| Institutional Ownership | +87.72% |
| Shares Outstanding | 29.77M |
| Float | 12.72M |
| Short % of Float | +22.29% |
Source: Nexqual, October 23, 2026 at 10:12 UTC.
Leadership (QTTB)
Q32 Bio Inc. is led by Jodie Pope Morrison, CEO & Director, per Nexqual as of October 23, 2026 at 10:12 UTC.
| CEO & Director | Jodie Pope Morrison |
|---|---|
| CFO & President | Lee H. Kalowski |
| Co-founder, Chief Scientific Officer & President of Research | Shelia M. Violette |
Major Backers & Investors (QTTB)
Notable institutional backers of Q32 Bio Inc. include Orbimed Advisors LLC., Boxer Capital Management, LLC, Atlas Venture Life Science Advisors, LLC , according to Nexqual as of October 23, 2026 at 10:12 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Orbimed Advisors LLC. | 13.87% |
| Boxer Capital Management, LLC | 10.58% |
| Atlas Venture Life Science Advisors, LLC | 9.13% |
| BVF Inc. | 7.89% |
| RA Capital Management, L.P. | 7.84% |
| Point72 Asset Management, L.P. | 3.94% |
| Opaleye Management Inc. | 3.13% |
| Logos Global Management LP | 2.69% |
Source: Nexqual, October 23, 2026 at 10:12 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 90.9 | ▲ 2.57% |
| LGND | Ligand Pharmaceuticals Incorpor | USD 307.82 | ▼ 2.21% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.14 | ▼ 3.28% |
| PRAX | Praxis Precision Medicines, Inc | USD 258.92 | ▲ 0.96% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 43.91 | ▼ 0.81% |
| ABVX | Abivax SA | USD 90.23 | ▼ 3.49% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:12 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt